checkAd

    Centrex Announces Closure of Private Placement - 500 Beiträge pro Seite

    eröffnet am 25.08.03 12:39:24 von
    neuester Beitrag 03.09.03 10:21:07 von
    Beiträge: 5
    ID: 767.982
    Aufrufe heute: 0
    Gesamt: 222
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 25.08.03 12:39:24
      Beitrag Nr. 1 ()
      (BSNS WIRE) Centrex Announces Closure of Private Placement with Joseph Steven
      & Co.
      Centrex Announces Closure of Private Placement with Joseph Stevens & Co.


      Business Editors/Health/Medical Writers

      TULSA, Okla.--(BUSINESS WIRE)--Aug. 25, 2003--Centrex (OTCBB:CNEX)
      today announced that the Company has raised approximately $730,000 in
      a private placement through Joseph Stevens & Co., Inc. In light of the
      JSCI financing, the Company has terminated its investment banking
      arrangement with H.D. Brous & Co. According to Dr. Thomas R. Coughlin,
      Jr., Centrex`s CEO, the funds will be used to support ongoing research
      at Los Alamos National Laboratory, to fund recently announced
      development agreements with Stratos Product Development, LLC and
      Micronics, Inc., and for general company operations. "We are
      attempting to accelerate the development of a highly advanced
      technology platform into products that will become powerful weapons
      against bioterrorism. In addition, mature versions of the technology
      have potential widespread applications in food and water processing,
      screening of the blood supply and the field of general DNA testing."

      About Joseph Stevens & Co. Inc.: Joseph Stevens & Co., Inc.
      ("JSCI") is a full service brokerage firm offering a variety of
      services. It is primarily engaged in the business of researching,
      purchasing and selling securities. However, as a registered
      broker-dealer, JSCI also offers other financial products, such as
      investment banking services, options, municipal and corporate bonds,
      and mutual funds. JSCI also publishes and distributes market research
      reports and letters as well as analyses of specific individual
      securities, whenever such publications are deemed appropriate. In
      addition, JSCI provides technical analysis of major indices for a wide
      range of securities, with a focus on technology, fixed income and
      currency markets. Its analysts often times are seen on financial media
      shows or events.
      JSCI clients include individuals, corporations, banks, thrift
      institutions, pension and profit sharing plans, Individual Retirement
      Accounts, Simplified Employee Pension accounts, trusts, estates,
      charitable organizations and other business entities.

      About Centrex, Inc.: Centrex, Inc., a development stage company,
      owns the exclusive worldwide license to develop, manufacture and
      market a system for the rapid, inexpensive and reliable detection of
      specific microbial contaminants in air, food and water. Centrex`s
      Single Molecule Detection (SMD) technology, developed at Los Alamos
      National Laboratory, recognizes specific nucleic acid sequences (DNA
      or RNA). SMD is an emerging field within bio-nanotechnology concerned
      with identification, classification, spatial orientation and
      manipulation of minute quantities of individual molecules. The Centrex
      SMD technology can quickly detect bacteria or viruses by identifying
      the DNA (or RNA) of the bacteria or virus. Contrasted with other types
      of DNA identification, SMD requires far smaller test samples and hence
      is very sensitive and fast. The SMD method is especially attractive
      for bioagent sensors because of its discrimination, accuracy and
      speed. It offers the potential for early warning combined with high
      sensitivity and accurate identification of biological weapons agents.
      The Centrex bioagent detection system is designed to be adaptable
      and easily tailored to detect a variety of bacterial or viral
      organisms through the unique genetic fingerprint of the organism. The
      proposed device is a simultaneous multi-channel detection system that
      is compact, fully automated and capable of monitoring the presence of
      microbial contaminants in air, food and water.
      For more information, visit the Centrex website at
      www.centrexcorporation.com, or call Darren Bankston, Centrex Investor
      Relations at 678-455-6914.

      This press release contains some forward-looking statements. We
      undertake no obligation to publicly update any forward-looking
      statement, whether as a result of new information, future events or
      otherwise. Forward-looking statements in this document should be
      evaluated together with the many uncertainties that affect our
      business. Those uncertainties are discussed in the Company`s SEC
      filings.

      --30--LR/da*
      Avatar
      schrieb am 25.08.03 12:41:47
      Beitrag Nr. 2 ()
      Avatar
      schrieb am 25.08.03 12:59:53
      Beitrag Nr. 3 ()
      ähnliche news letzte woche bei HIET

      und siehe da

      Avatar
      schrieb am 25.08.03 13:56:59
      Beitrag Nr. 4 ()
      Ich krieg die Tür nicht zu,
      mich beschimpfen als Centrex-Pusher und nun biste schneller :eek: :laugh: :laugh:

      Was macht denn deine MW Medical ?
      Sieht mau aus mit den Umsätzen, oder ?
      Naja du sagst ja die kommen noch.

      Warten wir mal ab, was Centrex heute macht, aber erwarte nicht zu viel :(
      Da ist momentan eine Sache, die erst geklärt werden muss, bevor Centrex richtig steigen kann, bei "schlechter" Nachricht gehts daneben !
      Gruß
      Avatar
      schrieb am 03.09.03 10:21:07
      Beitrag Nr. 5 ()
      Gibts was neues zu Centrex? Heute ja schon wieder 90.000 Stück Umsatz in Berlin. Was für einen Anlagehorizont habt Ihr bei dem Wert? 1 Jahr oder länger?


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Centrex Announces Closure of Private Placement